Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 27

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 27
---
 resulting measures that have been taken, and could be taken in the future,
by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created
global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing
conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit
and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any
resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in
capital markets.

Any
of the above-mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions
resulting from the Russian invasion of Ukraine, the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely
affect the Company’s search for an initial Business Combination and any target business with which the Company may ultimately consummate
an initial Business Combination. The unaudited financial statements do not include any adjustments that might result from the outcome
of this uncertainty.

Registration
Rights

The
holders of the Founder Shares, Private Placement Units (and underlying securities) and any Private Placement Units (and underlying
securities) that may be issued on conversion of working capital loans are entitled to registration rights pursuant to a registration
rights agreement requiring the Company to register such securities for resale. The holders of these securities are entitled to make up
to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have
certain piggy-back registration rights with respect to registration statements filed subsequent to the completion of the initial Business
Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act.
However, the registration rights agreement will provide that the Company will not be required to effect or permit any registration or
cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses
incurred in connection with the filing of any such registration statements.

14

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

Underwriting
Agreement

The
Company granted the underwriters a 45-day option from the date of the final prospectus